Secura Bio, Inc., a Henderson, NV-based integrated biopharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies, closed a $145m equity and debt financing.
The round includes:
– $55m equity financing from Funds managed by Athyrium Capital Management and Secura Bio executive team; and
– $90m debt financing with $50m initial tranche funded and additional $40m of funding available.
Led by Joseph M. Limber, President and Chief Executive Officer, Secura Bio is dedicated to the worldwide commercialization of significant oncology therapies for physicians and their patients.
The company was founded by a proven executive team that has collectively launched/relaunched over 20 significant therapeutic products. This team previously founded and managed numerous successful life science companies to acquisition or public offering including: Sequus (acquired by Alza/J&J); Praecis (acquired by GSK); Aclara (IPO); Gevo (IPO); Prometheus (acquired by Nestle Health Science); Agarigen (acquired by Intrexon); and Genoptix (acquired by NeoGenomics).